Aether Biomachines just sent a little voltage through the deep tech grid with a fresh $15M growth round led by Tribe Capital and Arjun Sethi. Natural Capital came back for another swing, Henkel Corporation joined with industrial precision, and the roster filled out with Resilience Reserve, Shrug Capital, 4DX Ventures, Unless Partners, and Radicle Impact. That kind of investor cocktail does not happen by accident. You only get VCs, strategics, and frontier funds in the same orbit when the tech is not promising to matter someday but is already bending markets today. The total raise hits $64M, and not a cent is pointed at theory. This is commercial gravity, not academic daydreaming.
Aether Biomachines, founded by Pavle Jeremić in 2017 alongside early co-founders Hannah Meyers and Chase Armer, has crossed that rare threshold where protein engineering stops being a lab hobby and becomes an industrial force. RapidPrint is already moving through 3D printers at speeds that turn the usual 30 to 80 mm/s into a nostalgic memory. Customers are clocking 300 to 450 mm/s without breaking a sweat, and a few are hitting 900 mm/s like they found a cheat code. Ultra Print delivers aluminum strength at half the weight with 40% carbon fiber absorption, pulling ahead of industry norms. These are shipping products, not speculative prototypes. You can feel the aerospace and defense sectors leaning in like engineers scouting untapped lift.
The secret weapon is the Aetheron Protein Function Model backed by millions of in-house experimental data points. Aether Biomachines is not scraping public datasets or chasing theoretical sequences. It is running the highest throughput robotic protein lab on the planet and coupling it with ML systems that learn through closed loop experimentation. The company is engineering molecular assemblers that operate in real industrial conditions, whether that means building next-gen composites, extracting lithium from overlooked sources with the potential to scale domestic output 30X, or working with partners like Allonnia on PFAS degradation. When a platform moves from predicting enzymes to manufacturing products that hit the aerospace floor, you know the center of gravity has shifted.
This new capital fuels a scale up of materials production, a push into European aerospace and defense markets, and the expansion of extraction technologies across regions like Oklahoma, Arkansas, and Texas. With leadership from Pavle Jeremić, Angelo Zhao, Galen Loving, Arjan Zoombelt, and Kelby Hull, the company is assembling momentum with intention. Investors like Jay Zaveri, Erik Scher, Shlomo Yanai, Austin Che, Stuart Peterson, and Vasudev Bailey know exactly what it means when a protein engineering platform starts producing at ton-scale. Aether Biomachines is not forecasting the future. It is manufacturing it in real time.
Startups Startup Funding Venture Capital AI Biotech Defense Defense Tech Aerospace Deep Tech Data Data Driven Robotics Robotic Tech Technology Innovation Tech Ecosystem Startup Ecosystem Hiring Tech Hiring
